← All stocks

TriSalus Life Sciences, Inc.

TLSI Net buying
CIK 0001826667 #3504 in the set updated 17 Sep 2026
Bought (12 mo)
$3.61M
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$135.81K
$0.00 on a plan · $0.00 straight out of an exercise
Sold at will
$135.81K
15 of 15 sales
Net
+$3.47M
+$3.47M against sales at will

By person

18 insiders · 27 transactions
4.4×

Mary Szela holds only 4.4 times base salary in stock. $2.65M of shares against $600.92K in salary for 2025.

Salary from the company's own proxy. The shares are what Mary Szela last reported holding, valued at $2.46, the price Common Stock was last bought or sold at on the open market here, on 15 May 2026.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Stansky Michael P
Director
$3.01M (4)
+$3.01M
1,640,420
$4.04M
+162.2%
Wahlstrom Mats
Director
$151.80K (1)
+$151.80K
147,555
$362.99K
Szela Mary T
CEO and President
$227.77K (2)
$79.38K (2)
+$148.39K
1,077,683
$2.65M
+108.0%
Valle William
Director
$125.00K (1)
+$125.00K
83,241
$204.77K
Gordon Gary B.
Director
$64.60K (2)
+$64.60K
72,510
$178.37K
Patience David
Chief Financial Officer
$32.25K (2)
+$32.25K
261,107
$642.32K
Marshak Richard
Chief Commercial Officer
$15.66K (4)
−$15.66K
128,319
$315.66K
+329.0%
Stevens Jennifer
Chief Regulatory Officer
$14.51K (3)
−$14.51K
124,110
$305.31K
+278.6%
Devlin Jodi
Chief of Clinical Operations
$13.17K (3)
−$13.17K
97,364
$239.52K
+536.1%
Cox Bryan F.
Chief of Research
$13.09K (3)
−$13.09K
163,415
$402.00K
+74.1%
Frankenius Equity AB
10% owner
6,989,748
$17.19M
+13.3%
MATLIN DAVID J
Director
1,323,210
$3.26M
+42.0%
HICKS KERRY R
Director
542,790
$1.34M
+5.5%
Murphy Sean
Director
321,721
$791.43K
+47.2%
Desai Arjun JJ
Director
247,127
$607.93K
−10.8%
Marshall Richard Henry
Chief Medical Officer
90,000
$221.40K
+200.0%
Young James Emmett
Chief Financial Officer
79,663
$195.97K
+763.5%
Hyveled Liselotte
Director
10,040
$24.70K

No percentages here. This company's share count has moved by a factor of 2.0 over the window, from 30,493,137 to 61,574,600 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Insider
Date
Role
Action
Shares
Price
Amount
Gordon Gary B.
15 May 2026
Director
Buy
10,000
$2.46
$24.60K
Patience David
15 May 2026
Chief Financial Officer
Buy
7,100
$2.43
$17.25K
Szela Mary T
15 May 2026
CEO and President
Buy
39,682
$2.59
$102.78K
Stansky Michael P
15 May 2026
Director
Buy indirect
200,000
$2.50
$500.00K
Stansky Michael P
15 May 2026
Director
Buy
410,000
$2.50
$1.03M
Wahlstrom Mats
15 May 2026
Director
Buy
60,000
$2.53
$151.80K
Stansky Michael P
23 Feb 2026
Director
Buy indirect
117,198
$4.10
$480.51K
Stansky Michael P
23 Feb 2026
Director
Buy
243,900
$4.10
$999.99K
Szela Mary T
23 Feb 2026
CEO and President
Buy
30,487
$4.10
$125.00K
Valle William
23 Feb 2026
Director
Buy
30,487
$4.10
$125.00K
Gordon Gary B.
23 Feb 2026
Director
Buy
9,756
$4.10
$40.00K
Patience David
23 Feb 2026
Chief Financial Officer
Buy
3,657
$4.10
$14.99K

What was left out

Form 4 filings counted 35
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 15
Transactions with no price 0
Shares from compensation/vesting 1,069,594
History held since 28 Dec 2020